Figure S3 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma

Supplemental Figure 3: RMC-7977 treatment leads to increased T cell infiltration. (A) Immunohistochemistry stained in red for CD8 of control (C, vehicle), responder (R, 3 days of treatment) and treatment escape (TE, 30 days of treatment). Scale bar = 200 µm. (B) Flow cytometry analysis of T cells (number of infiltrated CD4+ and CD8+ T cells, activated CD4+CD69+ and CD8+CD69+ T cells, and memory CD44+CD62L-CD4+ and CD44+CD62L-CD8+ T cells) of control, responder and treatment escape. (C) Multiplex IF scoring of whole slides stained for CD8, CD4, CD86, CD11b, CD11c, and Ly6G.